<DOC>
	<DOCNO>NCT01613404</DOCNO>
	<brief_summary>The purpose study compare 90 day 12 month composite end point death ( all-cause mortality ) hospitalization incident hemodialysis patient randomize receive support dedicate case manager ( intervention group ) versus receive support dedicate case manager ( control group ) .</brief_summary>
	<brief_title>An Observational Study Case Managed Versus Non-case Managed Initiation Hemodialysis</brief_title>
	<detailed_description>This multicenter , prospective , observational , randomize ( study drug assign chance ) , 1-year study , academic community-based nephrology clinical practice examine impact facility nurse case manager . In study group patient guideline- base , algorithm- driven approach hemodialysis initiation target ( per Canadian Society Nephrology and/or International guideline ) use facility nurse case manager control group approach use without facility nurse case manager . Patients treat approved erythropoiesis stimulate agent correction anemia , accord guidance current approve product monograph . All treatment prescribe physician accord actual clinical practice standard care chronic kidney disease . The entire study duration participant approximately 12 month .</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<criteria>Patients initiate hemodialysis expect hemodialysis least 1 year Patients initiate hemodialysis require treatment ( erythropoiesis stimulate agent red blood cell transfusion ) correct anemia chronic kidney disease receive erythropoiesis stimulate agent treatment study entry patient require erythropoiesis stimulating agent therapy ( Hb within target range ) Life expectancy 12 month Patients contraindicate receive erythropoiesis stimulate agent therapy ( include limited patient develop pure red cell aplasia follow treatment erythropoiesis stimulate agent ) Patients enter study agent increase red blood cell mass ( androgen therapy , investigational agent , nonapproved erythropoiesis stimulate agent ) Patients unwilling unable receive erythropoiesis stimulate agent therapy correct anemia chronic kidney disease Patients uncontrolled hypertension Patients reason receive adequate antithrombotic treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Chronic kidney disease</keyword>
	<keyword>Hemodialysis</keyword>
	<keyword>Eprex</keyword>
	<keyword>Aranesp</keyword>
	<keyword>ESA</keyword>
	<keyword>Anemia</keyword>
</DOC>